Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SLGC

Standard BioTools (SLGC) Stock Price, News & Analysis

Standard BioTools logo

About Standard BioTools Stock (NASDAQ:SLGC)

Key Stats

Today's Range
$1.93
$2.31
50-Day Range
$2.10
$2.83
52-Week Range
$1.73
$3.79
Volume
33.91 million shs
Average Volume
10.83 million shs
Market Capitalization
$394.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

Receive SLGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter.

SLGC Stock News Headlines

Standard BioTools Inc. Reports Q3 2024 Financial Performance
Nvidia’s world of pain awaits
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Standard BioTools CFO Jeffrey Black Resigns
See More Headlines

SLGC Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include Block (SQ), Digital Turbine (APPS), CrowdStrike (CRWD), SoFi Technologies (SOFI), Palantir Technologies (PLTR), Vuzix (VUZI) and Okta (OKTA).

Company Calendar

Today
12/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:SLGC
Fax
N/A
Employees
451
Year Founded
N/A

Profitability

Net Income
$-109,160,000.00
Net Margins
-159.54%
Pretax Margin
-159.08%

Debt

Sales & Book Value

Annual Sales
$97.67 million
Book Value
$3.00 per share

Miscellaneous

Free Float
160,049,000
Market Cap
$394.95 million
Optionable
Optionable
Beta
1.64
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:SLGC) was last updated on 12/4/2024 by MarketBeat.com Staff
From Our Partners